Physician profile
John E Deboard
NPI 1063572352
$6,167.55
in general payments reported to CMS, 2019-2025
29 companies · $669 in 2025
The $669 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,237 · 2020: $721 · 2021: $1,215 · 2022: $857 · 2023: $886 · 2024: $583 · 2025: $669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,022 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,022.06 |
| Education | $116.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $1,377.06 | 2019-2023 | |
| Novo Nordisk INC | $930.96 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $709.81 | 2019-2025 | Repatha, Evenity, Otezla |
| Lilly USA, LLC | $553.88 | 2019-2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $381.25 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $374.21 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $343.90 | 2019-2025 | |
| Glaxosmithkline, LLC. | $280.93 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $146.89 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $114.33 | 2019-2021 | |
| Dexcom, INC. | $106.73 | 2022-2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.90 | 2019-2025 | Jardiance |
| Radius Health, INC. | $93.45 | 2019-2021 | |
| Insulet Corporation | $90.58 | 2024-2025 | Omnipod |
| Sanofi-Aventis U.S. LLC | $69.31 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $58.89 | 2020 | |
| Merck Sharp & Dohme LLC | $55.48 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $52.29 | 2020-2023 | Livalo, Seglentis |
| Esperion Therapeutics, INC. | $44.93 | 2024-2025 | Nexletol |
| Abbvie INC. | $43.96 | 2023 | Ubrelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $39.66 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $38.48 | 2019-2020 | |
| Insmed, INC. | $30.75 | 2022 | |
| Astellas Pharma US INC | $22.05 | 2019 | |
| Eisai INC. | $21.98 | 2021 | |
| Teleflex LLC | $21.52 | 2025 | Urolift |
| Biohaven Pharmaceuticals, INC. | $19.96 | 2021 | |
| Genentech USA, INC. | $19.95 | 2020 | |
| Exact Sciences Corporation | $18.46 | 2025 | The Cologuard Plus Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Deboard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.